Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 3/20 | 0.63 |
| ▸ | RAB9A | P51151 | 3/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7824211 | 0.91 | KMT2A (0.68) | KMT2AKDM4EPOLBMAPK1CYP2C9 | |
| SCHEMBL9532980 | 0.90 | CYP2C9 (0.69) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL16404495 | 0.89 | KMT2A (0.69) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL7634493 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL4139016 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL1042215 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL5840193 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL2183707 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL7636178 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD | |
| SCHEMBL7629650 | 0.87 | SOAT1 (0.68) | KMT2AKDM4EPOLBCYP2C9HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099301-A2 | TREATMENTS FOR RESISTANT ACNE | Vyome Biosciences Pvt Ltd (IN) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015114666-A2 | TREATMENTS FOR RESISTANT ACNE | VYOME BIOSCIENCES PVT. LTD. (IN) | 2015-08-06 | — | — | WO | disclosed |
| US-8658656-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8470838-B2 | Quinazolinones useful for treating cellular proliferative diseases and disorders associated with KSP kinesin activity; N-(3-aminopropyl)-N-[(1R)-1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide monomethanesulfonate; treating breast cancer | CYTOKINETICS, INCORPORATED (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | FINER JEFFREY T (US) | 2013-02-28 | — | — | US | disclosed |
| US-8008311-B2 | Methods and compostions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | CYTOKINETICS, INC. | 2010-08-19 | — | — | US | disclosed |
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763628-B2 | Methods and compositions utilizing quinazolinones | CYTOKINETICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1296959-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001030768-A9 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS INC (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1226129-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | Cytokinetics, Inc. (US) | 2002-07-31 | — | — | EP | disclosed |
| EP-0815871-B1 | Tape plaster comprising anthranilic acid derivatives as percutaneous absorption promotors | LINTEC CORP (JP) | 2002-07-17 | — | — | EP | disclosed |
| WO-2001098278-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-12-27 | — | — | WO | disclosed |
| WO-2001030768-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | CYTOKINETICS, INC. (US) | 2001-05-03 | — | — | WO | disclosed |
| US-RE36138-E | AMINO ACID DERIVATIVE; DRUG DELIVERY | LINTEC CORPORATION (JP) | 1999-03-09 | — | — | US | disclosed |
| EP-0815871-A1 | A percutaneous absorption, a tape plaster and a method of promoting percutaneous absorption | LINTEC Corporation (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5413794-A | Drug delivery | LINTEC CORPORATION (JP) | 1995-05-09 | — | — | US | disclosed |
| EP-0552405-A1 | A percutaneous absorption promoter, a tape plaster and a method of promoting percutaneous absorption | LINTEC Corporation (JP) | 1993-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053408-A1 | METHODS AND COMPOSITIONS UTILIZING QUINAZOLINONES | KIF5B, KIF5C, KIF2C | KMT2A 1566/4885KDM4E 1216/4885POLB 185/4885 |
| US-20100210670-A1 | METHODS AND COMPOSTIONS UTILIZIING QUINAZOLINONES | KIF5B, KIF2C, KIF5C | KMT2A 1965/4885KDM4E 2226/4885POLB 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.